Sign in
Taking peopleNo phase

ALLOHEAL knee injection compared with Conjuran for knee osteoarthritis

Compares ALLOHEAL with Conjuran, injected into the knee, in people with knee osteoarthritis.

Key facts

Who runs it
Endovision Co., Ltd.
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Comparative Study on the Safety and Efficacy of the Intra-Articular Injectable Filler ALLOHEAL in Patients With Knee Osteoarthritis
Status
Recruiting
People taking part
286 people, planned
Started
4 Feb 2025
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ALLOHEAL
  • Conjuran
Record updated
7 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with knee osteoarthritis and knee pain. It compares the knee injection ALLOHEAL with the injection Conjuran.

Age
40 to under 80 years
Sex
Men and women
Disease stage
Knee osteoarthritis diagnosed by ACR guidelines within 24 weeks before screening or at screening. Kellgren-Lawrence grade I-III on X-ray. Knee pain for at least 8 weeks, with a weight-bearing pain score (VAS) of at least 40 mm. BMI less than 35 kg/m². Able to walk without a walker or cane, unless used for ≥24 weeks.
Earlier treatment
No surgery or arthroscopic treatment on the target knee within 24 weeks before screening.

Main reasons for not taking part

  • Needing surgery on the target knee, or loose knee ligaments of grade II or higher
  • Fracture or knee deformity of ≥10°, or infection, inflammation, severe fluid or skin problems at the knee
  • Rheumatoid arthritis, gout, fibromyalgia or other listed joint or connective tissue diseases
  • Severe liver, heart or kidney disease, cancer within the past 5 years, or bleeding disorders such as hemophilia
  • Allergy to pig-derived products or to parts of the study device

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • 1)Men and women aged ≥40 and <80 years at the date of signing the written informed consent; 2)Diagnosed with knee osteoarthritis according to the American College of Rheumatology (ACR) guidelines within 24 weeks prior to the screening visit or at the screening visit; 3)Experiencing pain in the osteoarthritic knee for at least 8 weeks. 4)At the screening visit, having a Kellgren-Lawrence grade I-III severity in the knee joint selected for evaluation based on X-ray findings (if both knees are symptomatic and show the same weight-bearing VAS score, the knee with the higher Kellgren-Lawrence grade will be selected as the target knee; the target knee cannot be changed during the clinical trial); 5)At the screening visit, having a weight-bearing VAS (Visual Analogue Scale) score of at least 40 mm in at least one knee joint (if both knees are symptomatic, the knee with the higher weight-bearing VAS score will be selected as the target knee; the target knee cannot be changed during the clinical trial); 6)At the screening visit, having a Body Mass Index (BMI) of less than 35 kg/m². 7)Able to walk without assistive devices such as a walker or cane (however, if the subject has been clinically using an assistive device for ≥24 weeks prior to the screening visit, assessment can be conducted including the device, and the same device must continue to be used until the completion of the trial); 8)Willing to voluntarily sign the written informed consent form. 9)Capable of understanding and complying with the procedures and visit schedule of the clinical trial

Who cannot take part

  • 1)History of surgical procedures (including meniscectomy or arthroscopic surgery) on the target knee within 24 weeks prior to the screening visit. (However, if the subject has a history of joint surgery on the contralateral knee, hip, or other joints that is unlikely to affect the clinical assessment of the target knee, participation in this clinical trial is allowed.) 2)History of arthroscopic treatment on the target knee within 24 weeks prior to the screening visit; 3)Requiring surgical intervention for the target knee at the screening visit. 4)Having ligament instability of grade II or higher in the target knee on physical examination at the screening visit (Grade 0: none, Grade I: 0-5 mm, Grade II: 5-10 mm, Grade III: >10 mm); 5)Presence of orthopedic conditions such as fractures or joint deformities in the target knee that may affect or interfere with treatment efficacy (joint deformity refers to varus or valgus deformity ≥10° in the knee joint); 6)Experiencing pain in the target knee due to surrounding joint structures or coexisting osteoarthritis in other areas (e.g., hip) that may influence assessment of knee pain; 7)Presence of the following comorbidities: Rheumatoid arthritis, spondyloarthritis, connective tissue disease, polymyalgia rheumatica, gout, Paget's disease, septic arthritis, psoriatic arthritis, joint fractures, osteonecrosis, fibromyalgia, chondrocalcinosis
  • Severe hepatic, cardiac, or renal disease
  • Malignant tumors within the past 5 years
  • Coagulation disorders such as hemophilia 8) Infection or inflammation in the target knee joint. 9) Severe effusion in the target knee joint. 10) Local skin disorders at the target knee. 11)Hypersensitivity to porcine-derived products. 12)Hypersensitivity or history of adverse reactions to the main or other components of the investigational medical device used in this clinical trial
  • Amyloidosis

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

ENDOVISION Co., Ltd. has developed an intra-articular knee injection with sodium polynucleotide, chitosan, and type I collagen as its main components, and aims to demonstrate the non-inferiority of the investigational device, ALLOHEAL, compared with the control device, Conjuran®, when administered intra-articularly to patients with knee osteoarthritis for the purpose of reducing mechanical friction within the joint cavity.

The 2 groups in the trial

  • ALLOHEAL GroupTreatment being tested

    Treatment: ALLOHEAL

  • Comparator GroupExisting treatment, for comparison

    Treatment: Conjuran

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority, Pivotal Clinical Study to Evaluate the Safety and Efficacy of Intra-articular Filler 'ALLOHEAL' in Knee Osteoarthritis Patients
Plain-language title
ALLOHEAL knee injection compared with Conjuran for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07513415, who can take part
Record updated
7 April 2026